MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE: COV) and Masimo today announced that they have amended the existing settlement agreement initially reached in January 2006. Under the terms of the amendment, Covidien will pay Masimo a royalty of 7.75% for its current pulse oximetry products sold in the United States for three years, beginning March 15, 2011.
